Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Neutral” Rating from Cantor Fitzgerald

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “neutral” rating reiterated by research analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $1,015.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential downside of 12.15% from the stock’s current price.

Several other brokerages have also recently issued reports on REGN. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Argus increased their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. TD Cowen raised their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,109.70.

Regeneron Pharmaceuticals Trading Up 0.2 %

Shares of REGN stock traded up $1.98 on Monday, reaching $1,155.33. 75,690 shares of the company’s stock were exchanged, compared to its average volume of 465,828. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The company’s fifty day simple moving average is $1,124.22 and its 200 day simple moving average is $1,026.46. The stock has a market capitalization of $127.30 billion, a PE ratio of 34.13, a P/E/G ratio of 3.97 and a beta of 0.12. Regeneron Pharmaceuticals has a 52 week low of $769.19 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period in the previous year, the company posted $8.79 EPS. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,467,684. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,026 shares of company stock worth $11,498,705. Corporate insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in REGN. Vanguard Group Inc. boosted its position in Regeneron Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after purchasing an additional 91,956 shares during the last quarter. Capital World Investors increased its stake in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after buying an additional 23,146 shares during the period. Capital International Investors increased its stake in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the period. Putnam Investments LLC grew its stake in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after purchasing an additional 24,329 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after acquiring an additional 184,561 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.